FDA panel supports approval of Boehringer's olodaterol for COPD

An FDA advisory panel endorsed the approval of Boehringer Ingelheim's olodaterol as a once-daily bronchodilator treatment for chronic obstructive pulmonary disease including chronic bronchitis and emphysema. Boehringer plans to market the drug in a soft mist inhaler under the name Striverdi Respimat.

View Full Article in:

Bloomberg Businessweek · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ